<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32029539</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Primary lateral sclerosis: consensus diagnostic criteria.</ArticleTitle><Pagination><StartPage>373</StartPage><EndPage>377</EndPage><MedlinePgn>373-377</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2019-322541</ELocationID><Abstract><AbstractText>Primary lateral sclerosis (PLS) is a neurodegenerative disorder of the adult motor system. Characterised by a slowly progressive upper motor neuron syndrome, the diagnosis is clinical, after exclusion of structural, neurodegenerative and metabolic mimics. Differentiation of PLS from upper motor neuron-predominant forms of amyotrophic lateral sclerosis remains a significant challenge in the early symptomatic phase of both disorders, with ongoing debate as to whether they form a clinical and histopathological continuum. Current diagnostic criteria for PLS may be a barrier to therapeutic development, requiring long delays between symptom onset and formal diagnosis. While new technologies sensitive to both upper and lower motor neuron involvement may ultimately resolve controversies in the diagnosis of PLS, we present updated consensus diagnostic criteria with the aim of reducing diagnostic delay, optimising therapeutic trial design and catalysing the development of disease-modifying therapy.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK martin.turner@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barohn</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, The University of Kansas Medical Center, Kansas City, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neurology, CHRU Bretonneau, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>John K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Neurology, Columbia University College of Physicians and Surgeons, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Bushell Chair of Neurology, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurosciences, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology &amp; Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neurology, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Statland</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0790-5315</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The University of Kansas Medical Center, Kansas City, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Delegates of the 2nd International PLS Conference</CollectiveName></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurology, Columbia University College of Physicians and Surgeons, New York City, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG062268</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH120794</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R13 NS111790</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: MRT is on the Scientific Advisory Board for Orphazyme, has been a paid consultant for Genentech Inc. (2017) and anonymous clients separately through GLG Consulting on the topic of ALS diagnosis, management and biomarker development. He received neurofilament assay kits in-kind from Euroimmun UK (2018).PC has reveived honoraria from Biogen &amp; Cytokinetics. ZS has received honoraria from Wiley, Cytokinetics &amp; Biohaven. HM is on the Advisory Board of Mitsubishi-Tanabe &amp; Biohaven.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Ajroud-Driss</LastName><ForeName>Senda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bede</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chew</LastName><ForeName>Sheena</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conwit</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Mamede de</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivian E</ForeName><Initials>VE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>M Fernandes</LastName><ForeName>J Americo</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrey</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finegan</LastName><ForeName>Eoin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Floeter</LastName><ForeName>Mary Kay</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina N</ForeName><Initials>CN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Govindarajan</LastName><ForeName>Raghav</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayat</LastName><ForeName>Ghazala</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xfc;bers</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jawdat</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kano</LastName><ForeName>Osamu</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kisanuki</LastName><ForeName>Yaz Y</ForeName><Initials>YY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marren</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morita</LastName><ForeName>Mitsuya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nations</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pullman</LastName><ForeName>Seth L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rezania</LastName><ForeName>Kourosh</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scelsa</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siddique</LastName><ForeName>Nailah</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solano</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blitterswijk</LastName><ForeName>Marka van</ForeName><Initials>MV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Cuiping</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lange</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32029539</ArticleId><ArticleId IdType="pmc">PMC7147236</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId><ArticleId IdType="pii">jnnp-2019-322541</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stark FM, Moersch FP. Primary lateral sclerosis: a distinct clinical entity. J Nerv Ment Dis 1945;102:332&#x2013;7.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, et al. . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740&#x2013;6. 10.1136/jnnp.2010.235952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico E, Pasmantier M, Lee Y-W, et al. . Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). Muscle Nerve 2013;47:28&#x2013;32. 10.1002/mus.23496</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23496</ArticleId><ArticleId IdType="pmc">PMC3528840</ArticleId><ArticleId IdType="pubmed">23169452</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringle CE, Hudson AJ, Munoz DG, et al. . Primary lateral sclerosis. clinical features, neuropathology and diagnostic criteria. Brain 1992;115:495&#x2013;520. 10.1093/brain/115.2.495</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/115.2.495</ArticleId><ArticleId IdType="pubmed">1606479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, et al. . The natural history of primary lateral sclerosis. Neurology 2006;66:647&#x2013;53. 10.1212/01.wnl.0000200962.94777.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000200962.94777.71</ArticleId><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C-F, Kakita A, Piao Y-S, et al. . Primary lateral sclerosis: a rare upper-motor-predominant form of amyotrophic lateral sclerosis often accompanied by frontotemporal lobar degeneration with ubiquitinated neuronal inclusions? report of an autopsy case and a review of the literature. Acta Neuropathol 2003;105:615&#x2013;20. 10.1007/s00401-003-0687-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0687-0</ArticleId><ArticleId IdType="pubmed">12734667</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Josephs KA, Amador-Ortiz C. Tdp-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol 2007;114:71&#x2013;9. 10.1007/s00401-007-0234-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0234-5</ArticleId><ArticleId IdType="pubmed">17569066</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer MA, Statland JM, Wolfe GI, et al. . Primary lateral sclerosis. Muscle Nerve 2007;35:291&#x2013;302. 10.1002/mus.20728</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20728</ArticleId><ArticleId IdType="pubmed">17212349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai P, Pagan F, Statland J, et al. . Primary lateral sclerosis: a heterogeneous disorder composed of different subtypes? Neurology 2003;60:1258&#x2013;65. 10.1212/01.WNL.0000058900.02672.D2</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000058900.02672.D2</ArticleId><ArticleId IdType="pubmed">12707427</ArticleId></ArticleIdList></Reference><Reference><Citation>Norlinah IM, Bhatia KP, &#xd8;stergaard K, et al. . Primary lateral sclerosis mimicking atypical parkinsonism. Mov Disord 2007;22:2057&#x2013;62. 10.1002/mds.21645</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21645</ArticleId><ArticleId IdType="pubmed">17702034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabuchi N, Watanabe H, Atsuta N, et al. . Primary lateral sclerosis presenting parkinsonian symptoms without nigrostriatal involvement. J Neurol Neurosurg Psychiatry 2004;75:1768&#x2013;71. 10.1136/jnnp.2003.035212</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.035212</ArticleId><ArticleId IdType="pmc">PMC1738849</ArticleId><ArticleId IdType="pubmed">15548503</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries BS, Rustemeijer LMM, Bakker LA, et al. . Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes. J Neurol Neurosurg Psychiatry 2019;90:141&#x2013;7. 10.1136/jnnp-2018-318788</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318788</ArticleId><ArticleId IdType="pubmed">30076267</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Highton-Williamson E, Caga J, et al. . Primary lateral sclerosis and the amyotrophic lateral sclerosis&#x2013;frontotemporal dementia spectrum. J Neurol 2018;265:1819&#x2013;28. 10.1007/s00415-018-8917-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8917-5</ArticleId><ArticleId IdType="pubmed">29868980</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. The reunification of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:122&#x2013;3. 10.1136/jnnp-2018-319470</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319470</ArticleId><ArticleId IdType="pubmed">30297521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills CK. Unilateral ascending paralysis and unilateral descending paralysis. their clinical varieties and their pathological causes. JAMA 1906;20:1638&#x2013;45.</Citation></Reference><Reference><Citation>Keegan BM, Kaufmann TJ, Weinshenker BG, et al. . Progressive solitary sclerosis: gradual motor impairment from a single CNS demyelinating lesion. Neurology 2016;87:1713&#x2013;9. 10.1212/WNL.0000000000003235</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003235</ArticleId><ArticleId IdType="pmc">PMC5085075</ArticleId><ArticleId IdType="pubmed">27638926</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastaut JL, Bartolomei F. Mills' syndrome: ascending (or descending) progressive hemiplegia: a hemiplegic form of primary lateral sclerosis? J Neurol Neurosurg Psychiatry 1994;57:1280&#x2013;1. 10.1136/jnnp.57.10.1280</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.10.1280</ArticleId><ArticleId IdType="pmc">PMC485513</ArticleId><ArticleId IdType="pubmed">7931406</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuipers-Upmeijer J, de Jager AE, Hew JM. Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings. JNeurolNeurosurgPsychiatry 2001;71:615&#x2013;20. 10.1136/jnnp.71.5.615</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.71.5.615</ArticleId><ArticleId IdType="pmc">PMC1737610</ArticleId><ArticleId IdType="pubmed">11606672</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Forestier N, Maisonobe T, Piquard A, et al. . Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 2001;124:1989&#x2013;99. 10.1093/brain/124.10.1989</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/124.10.1989</ArticleId><ArticleId IdType="pubmed">11571217</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer MA, Kojan S, Barohn RJ, et al. . Primary lateral sclerosis: clinical and laboratory features in 25 patients. J Clin Neuromuscul Dis 2005;7:1&#x2013;9. 10.1097/01.cnd.0000176974.61136.45</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.cnd.0000176974.61136.45</ArticleId><ArticleId IdType="pubmed">19078775</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Nagy PL, Gennings C, et al. . Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet 2015;1:e3 10.1212/01.NXG.0000464294.88607.dd</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.NXG.0000464294.88607.dd</ArticleId><ArticleId IdType="pmc">PMC4821084</ArticleId><ArticleId IdType="pubmed">27066542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Murphy A, Loci L, et al. . Primary lateral sclerosis and early upper motor neuron disease: characteristics of a cross-sectional population. J Clin Neuromuscul Dis 2016;17:99&#x2013;105. 10.1097/CND.0000000000000102</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0000000000000102</ArticleId><ArticleId IdType="pmc">PMC4770823</ArticleId><ArticleId IdType="pubmed">26905909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wais V, Rosenbohm A, Petri S, et al. . The concept and diagnostic criteria of primary lateral sclerosis. Acta Neurol Scand 2017;136:204&#x2013;11. 10.1111/ane.12713</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12713</ArticleId><ArticleId IdType="pubmed">27858953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink JK. Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Semin Neurol 2001;21:199&#x2013;208. 10.1055/s-2001-15265</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2001-15265</ArticleId><ArticleId IdType="pubmed">11442328</ArticleId></ArticleIdList></Reference><Reference><Citation>Brugman F, Veldink JH, Franssen H, et al. . Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol 2009;66:509&#x2013;14. 10.1001/archneurol.2009.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.19</ArticleId><ArticleId IdType="pubmed">19364936</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, Simon NG, Grosskreutz J, et al. . Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clinical Neurophysiology 2016;127:2643&#x2013;60. 10.1016/j.clinph.2016.04.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2016.04.025</ArticleId><ArticleId IdType="pubmed">27291884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji Y, Noto Y-ichi, Shiga K, et al. . A muscle ultrasound score in the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology 2017;128:1069&#x2013;74. 10.1016/j.clinph.2017.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2017.02.015</ArticleId><ArticleId IdType="pubmed">28343888</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto Y-I, Shibuya K, Shahrizaila N, et al. . Detection of fasciculations in amyotrophic lateral sclerosis: the optimal ultrasound scan time. Muscle Nerve 2017;56:1068&#x2013;71. 10.1002/mus.25607</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25607</ArticleId><ArticleId IdType="pubmed">28187527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsugawa J, Dharmadasa T, Ma Y, et al. . Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clin Neurophysiol 2018;129:2149&#x2013;54. 10.1016/j.clinph.2018.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.07.015</ArticleId><ArticleId IdType="pubmed">30114663</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Sue CM, et al. . Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia. Eur J Neurol 2015;22:826&#x2013;58. 10.1111/ene.12669</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12669</ArticleId><ArticleId IdType="pubmed">25683471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher KM, Zaaimi B, Williams TL, et al. . Beta-Band intermuscular coherence: a novel biomarker of upper motor neuron dysfunction in motor neuron disease. Brain 2012;135:2849&#x2013;64. 10.1093/brain/aws150</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws150</ArticleId><ArticleId IdType="pmc">PMC3437020</ArticleId><ArticleId IdType="pubmed">22734124</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, van Ede F, Quinn A, et al. . Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. Clin Neurophysiol 2018;129:1479&#x2013;89. 10.1016/j.clinph.2018.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.03.019</ArticleId><ArticleId IdType="pubmed">29678369</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20. 10.1136/jnnp-2015-311387</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Bampton A, et al. . Csf chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:1215&#x2013;20. 10.1136/jnnp-2019-320442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Claassen DO, Josephs KA, Peller PJ. The stripe of primary lateral sclerosis: focal primary motor cortex hypometabolism seen on fluorodeoxyglucose F18 positron emission tomography. Arch Neurol 2010;67:122&#x2013;5. 10.1001/archneurol.2009.298</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.298</ArticleId><ArticleId IdType="pubmed">20065142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarelli O, Behrens TE, Johansen-Berg H, et al. . Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. Hum Brain Mapp 2009;30:615&#x2013;24. 10.1002/hbm.20527</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20527</ArticleId><ArticleId IdType="pmc">PMC6870826</ArticleId><ArticleId IdType="pubmed">18172851</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata NK, Kwan JY, Danielian LE, et al. . White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain 2011;134:2642&#x2013;55. 10.1093/brain/awr178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr178</ArticleId><ArticleId IdType="pmc">PMC3170531</ArticleId><ArticleId IdType="pubmed">21798965</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Chipika RH, Li Hi Shing S, et al. . The clinical and radiological profile of primary lateral sclerosis: a population-based study. J Neurol 2019;266:2718&#x2013;33. 10.1007/s00415-019-09473-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09473-z</ArticleId><ArticleId IdType="pubmed">31325016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu S, Menke RAL, Talbot K, et al. . Cerebellar tract alterations in PLS and ALS. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:281&#x2013;4. 10.1080/21678421.2018.1562554</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1562554</ArticleId><ArticleId IdType="pubmed">30663900</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabes J, Matthews L, Filippini N, et al. . Quantitative FLAIR MRI in amyotrophic lateral sclerosis. Acad Radiol 2017;24:1187&#x2013;94. 10.1016/j.acra.2017.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2017.04.008</ArticleId><ArticleId IdType="pmc">PMC5605225</ArticleId><ArticleId IdType="pubmed">28572001</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer AD, Liu T, Gupta A, et al. . Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis. AJR Am J Roentgenol 2015;204:1086&#x2013;92. 10.2214/AJR.14.13459</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.14.13459</ArticleId><ArticleId IdType="pmc">PMC4889122</ArticleId><ArticleId IdType="pubmed">25905946</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Westeneng H-J, Meier JM, et al. . Cross-Sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease. Neuroimage 2019;24:101984 10.1016/j.nicl.2019.101984</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101984</ArticleId><ArticleId IdType="pmc">PMC6734179</ArticleId><ArticleId IdType="pubmed">31499409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>